TOP 5 DRUGS.. TO AVOID IN THE ELDERLY
|
|
- Alberta Cook
- 5 years ago
- Views:
Transcription
1 TOP 5 DRUGS.. TO AVOID IN THE ELDERLY Debbie Kwan, BScPhm., MSc., FCSHP Canadian Geriatrics Society, April 20, 2013
2 Disclosure of Potential for Conflict of Interest: Financial Disclosure: None
3 Mar 26, 2013
4 Seniors and Polypharmacy: 63% - claims for 5 drug classes 23% - claims for 10 drug classes Ontario (2007): Cost of ADR-related emergency department visits/hospitalizations: $35 m CIHI 2009 Wu et al., Drug Saf 2012; 35(9):
5 Why are the elderly at risk: Age-related changes: Pharmacokinetic Pharmacodynamic Lack of guidelines: Elderly underrepresented Time to benefit
6 Medications and the Elderly BEERS 2012 update START/STOPP O Mahoney et al., 2010 McLeod et al., 1997
7 Drug-related Emergency Room visits: Common culprits Insulin Opioids Anticoagulants Digoxin Antihistamine/cold products Many are preventable Top 3? Budnitz et al., JAMA 2006 Zed et al, CMAJ 2008; 178:
8 Selecting the Top 5 Q: How many prescriptions were dispensed in Canada in 2012? >550 million! Commonly used Not absolutely contraindicated Consider using LESS often Reasonable alternatives available Open dialogue
9 1. NSAIDS
10 Case 1 - Arlene 68 yr old TIA ASA 325 mg Hypertension lisinopril, hydrochlorothiazide Osteoarthritis celecoxib, naproxen (OTC) BP 175/95
11 NSAIDs / COX-2 inhibitors Widely available (Rx and OTC) Risks: GI bleed, peptic ulcer disease Exacerbation of: hypertension heart failure Deterioration in renal function Many adverse effects are dose related and reversible
12 ?? High risk: NSAIDs & GI toxicity 1. Previously complicated ulcer 2. Multiple (> 2) risk factors Moderate risk (1-2 risk factors) 1. Age > 65 yr 2. High dose NSAID therapy 3. Previous history of uncomplicated ulcer 4. Concurrent use of ASA (incl. low dose), corticosteroids or anticoagulants Low risk: 1. No risk factors Lanza et al, Am J Gastroenterol 2009; 104: H. pylori: independent and additive risk factor Ulcer prophylaxis? 1. Misoprostol ( 200 ug TID) 2. PPI
13 Impaired Glomerular Autoregulation NSAIDS / COX-2 inhibitors ACEI/ARB Na, BP diuretics plasma volume & renal perfusion
14 Alternatives for OA pain: Acetaminophen Non-pharm (weight loss, pool therapy, appropriate joint protection, aids) Minimize systemic NSAID exposure Decrease ASA: 81 mg/d Topicals: diclofenac, methylsalicylate Gastroprotection: not H2RA or diclofenac/misoprostol BID (e.g. Arthrotec ) PPI ACR 2012 guidelines
15 2. GLYBURIDE
16 Case 2 Joe 83 yr old T2 DM - AIC 8.0% Lives alone Glyburide 7.5 mg bid Metformin 500 mg bid ER x 2 -> confusion ; disruptive behavior -> hypoglycemia
17 Glyburide Sulfonylurea Top 100 Rank? Concerns: #65 Hypoglycemia 21% per year (UKPDS) Elderly: lack of recognition / asymptomatic consequences: falls, fractures, seizures Mechanism: Active metabolite: accumulates in renal (and hepatic) dysfunction Long duration of action (24 + hr)
18 CDA 2013 guidelines How low should we go? 8.0%
19 Safer alternatives for Joe Hypoglycemic risk Dosing Use in renal insufficiency Glimepiride Low Daily X Gliclazide Lowest Daily DPP-4 inhibitor None Daily Adjust dose ODB A1C 8% - continue Metformin alone?
20 3. GABAPENTIN #51
21 Case 3 Mildred 79 yr Chronic pain (fibromyalgia) Gabapentin 600 mg TID
22 Gabapentin: Indication: anticonvulsant 80% sales off-label use (e.g. neuropathic pain, migraine, mood stabilizer) Aggressive marketing Publication bias towards benefit: Published trials: 1 in 3 patients will benefit vs. Unpublished + published trials: 1 in 8 patients Harms: 1 in 8 patient s will suffer adverse event Efficacy (< 900 mg/d) vs. harm with dose N Engl J Med Jan 8;360(2):103-6.;
23 Gabapentin 100% renal excretion (not metabolized) Adjust dose in renal impairment Side effects (> 10%) Somnolence, Fatigue, Ataxia, Dizziness Caution in patients at risk of: Cognitive impairment Balance disturbance Falls Peripheral vascular disease Elderly
24 Alternatives for Mildred Pregabalin better? Similar side effect profile Renal excretion Duloxetine? Non-Pharm strategies?
25 4. DES ES Try this instead!
26 Enantiomers ( Des Es ) Examples Esomeprazole (Nexium ) Escitalopram (Cipralex ) Desvenlafaxine (Pristiq ) Desloratidine (Aerius ) Are they more efficacious? Cost implications
27 5. DOCUSATE
28 Docusate #21 / Top 100!? Effectiveness in chronic constipation Implications: pill burden -> adherence, cost Choosing more appropriate laxatives opioid therapy stimulants chronic constipation - lactulose, PEG, bulk-forming Clinical Evidence: Constipation in adults
29 Medication Non-Adherence 50% prevalence in the elderly Adherence as # of medications Barriers: Too many pills Complex schedules Cost Intentional non-adherence Hajjar ER, Am J Ger Pharm 2007; 5(4):
30 Improving Medication Adherence: Multi factorial Reduce pill burden Combination products Engage in deprescribing When to taper vs. stop Simplify medication schedules (timing, tablet splitting, alternate strengths)
31 Objectives/Summary: Can you? 1. Recognize drugs that should be used less often in the elderly. 2. Describe the potential adverse effects that can occur as a result of using these drugs in the elderly population. 3. Prescribe safer therapeutic alternatives.
32 Free online resources: Drug interactions: Clinical search engine: Drugs and the elderly: BEERS: Academic detailing Dalhousie University Therapeutics Initiative UBC Rx Files (selected info free):
33 THANK YOU! Acknowledgement: Derek Jorgenson, Pharm.D, University of Saskatchewan
Deconstructing Polypharmacy. Alan B. Douglass, M.D. Director
Deconstructing Polypharmacy Alan B. Douglass, M.D. Director Recognize this patient? Mrs. Brown- 82 years young Active Medical Problems Hypertension Hyperlipidemia Type 2 Diabetes Peripheral edema Osteoarthritis
More informationIf Not Opioids then LEAH EDMONDS CSHP OCTOBER 26, 2017
If Not Opioids then what LEAH EDMONDS CSHP OCTOBER 26, 2017 Disclosure Nothing to disclose Objectives Identify various non-opioid options for the treatment of chronic non cancer pain Choose appropriate
More informationDEPRESCRIBING IN THE ELDERLY
DEPRESCRIBING IN THE ELDERLY G E R I A T R I C S R E F R E S H E R D A Y W E D N E S D A Y, A P R I L 5 TH, 2 0 1 7 V É R O N I Q U E F R E N C H M E R K L E Y, M D, C C F P ( C O E ) B R U Y È R E C O
More informationPolypharmacy. Polypharmacy. Suboptimal Prescribing in Older Adults. Kenneth Schmader, MD Professor of Medicine-Geriatrics
Polypharmacy Kenneth Schmader, MD Professor of Medicine-Geriatrics Polypharmacy Definition Causes Consequences Prevention/management Suboptimal Prescribing in Older Adults Overuse Polypharmacy Underuse
More informationA Process for Performing Medication Assessments
A Process for Performing Medication Assessments Derek Jorgenson, BSP, PharmD, FCSHP College of Pharmacy and Nutrition University of Saskatchewan Objectives 1. Learn an overview of a medication assessment
More informationPolypharmacy and Polymorbid Patients: Practical Tips and Tricks
Polypharmacy and Polymorbid Patients: Practical Tips and Tricks November 2, 2013 Faculty/Presenter Disclosure Faculty: Chris Fan-Lun, BScPhm, ACPR, CGP Pharmacist - Geriatric Medicine Clinical Practice
More informationA C A D E M I C D E TA I L I N G C H O O S I N G W I S E LY C O N F E R E N C E O C T 2 1, PA M M C L E A N - V E Y S E Y B S C P H A R M D R
PPI DEPRESCRIBING Canadian Deprescribing Network (CaDeN) goals are to: Reduce harm by raising awareness and cutting risky prescriptions for seniors by 50% by 2020. Promote health by ensuring access to
More informationSTART, STOPP, Beers Oh My! Navigating the World of Geriatric Pharmacy
START, STOPP, Beers Oh My! Navigating the World of Geriatric Pharmacy Jessica DiLeo, PharmD Kate Murphy, PharmD OBJECTIVES Identify pharmacodynamic and pharmacokinetic parameters that may influence treatment
More informationDiabetes and the Elderly: Medication Considerations When Determining Benefits and Risks
Diabetes and the Elderly: Medication Considerations When Determining Benefits and Risks Gretchen M. Ray, PharmD, PhC, BCACP, CDE Associate Professor UNM College of Pharmacy September 7 th, 2018 DISCLOSURES
More informationDeprescribing in CKD patients: Is less more? Speaker: Dr. Judith G. Marin, PharmD
2016 Deprescribing in CKD patients: Is less more? Speaker: Dr. Judith G. Marin, PharmD Case Mr. Kid Ney is a 75 y/o patient who has been on dialysis for the last 4 years (PD, then HD). PMHx: HTN, DM,
More informationDisclosures. Use caution in the elderly: review of safe and effective medication use in older patients. Institute of Medicine. Learning Objectives
Use caution in the elderly: review of safe and effective medication use in older patients Disclosures I have no disclosures or conflicts of interest related to this presentation John T. Holmes, PharmD,
More informationGeriatric Pharmacology
Geriatric Pharmacology Janice Scheufler R.Ph.,PharmD, FASCP Clinical Pharmacist Hospice of the Western Reserve Objectives List three risk factors for adverse drug events in the elderly Discuss two physiological
More information3/1/2018. Disclosures. Objectives. Clinical advisory board member- Daiichi Sankyo
Adjuvant pain medications in geriatrics Thomas B. Gregory, Pharm.D., BCPS, CPE, FASPE Clinical Pharmacy Specialist Pain Management CoxHealth Springfield, MO Disclosures Clinical advisory board member-
More informationSUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP)
9 SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP) SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF ACUTE PAIN NONOPIOID TREATMENTS
More informationKnock Out Opioid Abuse in New Jersey:
Knock Out Opioid Abuse in New Jersey: A Resource for Safer Prescribing GUIDELINE FOR PRESCRIBING OPIOIDS FOR CHRONIC PAIN IMPROVING PRACTICE THROUGH RECOMMENDATIONS CDC s Guideline for Prescribing Opioids
More information1/21/2016 UPDATE ON THE AMERICAN GERIATRICS SOCIETY 2015 BEERS CRITERIA DISCLOSURE OBJECTIVES AGING GOALS BEERS CRITERIA
UPDATE ON THE AMERICAN GERIATRICS SOCIETY 2015 BEERS CRITERIA DISCLOSURE I have no financial conflict of interest to disclose. Lacey Charbonneau, Pharm.D. PGY-1 Community Practice Resident Baptist Medical
More informationAbout ISMP Canada. Analysis Outputs: Safety Bulletins. Less is More: An Introduction to Deprescribing. canada.org
Less is More: An Introduction to Deprescribing Lindsay Yoo, BSc, BScPhm, RPh, CDE, CGP, PharmD Medication Safety Analyst, ISMP Canada About ISMP Canada The Institute for Safe Medication Practices Canada
More informationPolypharmacy & De-prescribing In Older Adults
Polypharmacy & De-prescribing In Older Adults Maryland Association of Osteopathic Physicians Annual Meeting September 15, 2018 Elizabeth Phung, DO Lead Clinical Associate Physician Beacham Center for Geriatric
More informationPain therapeutics. Acetaminophen/NSAIDs Acute pain Osteoarthritis Migraine Acute Gout Neuropathic pain
Pain therapeutics Acetaminophen/NSAIDs Acute pain Osteoarthritis Migraine Acute Gout Neuropathic pain James McCormack, Pharm.D. Professor Faculty of Pharmaceutical Sciences, UBC Common types of pain killers
More informationCanadian Diabetes Association 2013
Spring 2014 Canadian Diabetes Association 2013 clinical practice guidelines - Do claims data align to the guidelines? Canadian Diabetes Association 2013 clinical practice guidelines - Do claims data align
More informationPRESCRIBING IN THE ELDERLY. CARE HOME PHARMACY TEAM Bhavini Shah, Eleesha Pentiah & Puja Vyas
PRESCRIBING IN THE ELDERLY CARE HOME PHARMACY TEAM Bhavini Shah, Eleesha Pentiah & Puja Vyas LEARNING OUTCOMES Medicines Optimisation The effects of aging on health and medicines. Polypharmacy Acute Kidney
More informationCARDIOVASCULAR RISK and NSAIDs
CARDIOVASCULAR RISK and NSAIDs Dr. Syed Ghulam Mogni Mowla Assistant Professor of Medicine Shaheed Suhrawardy Medical College, Dhaka INTRODUCTION NSAIDs are most commonly prescribed drugs Recent evidence
More informationGateshead Pain Guidelines for Chronic Conditions
Gateshead Pain Guidelines for Chronic Conditions Effective Date: 13.2.2013 Review Date: 13.2.2015 Gateshead Pain Guidelines: Contents PAIN GUIDELINES Chronic Non-Malignant Pain 5 Musculoskeletal Pain 6
More informationMucky Meds: A (practical) approach the nightmare med list. Michelle Gibson, MD, CCFP (COE), FCFP and Erin Beattie, MD, CCFP
Mucky Meds: A (practical) approach the nightmare med list Michelle Gibson, MD, CCFP (COE), FCFP and Erin Beattie, MD, CCFP Faculty/Presenter Disclosure Faculty: Michelle Gibson Relationships with financial
More informationGeriatric Pharmacology. Kwi Bulow, M.D. Clinical Professor of Medicine Director, Academic Geriatric Resource Center
Geriatric Pharmacology Kwi Bulow, M.D. Clinical Professor of Medicine Director, Academic Geriatric Resource Center Silver Tsunami 2010: 40 million (13%) 2030: 72 million (20%) Baby Boomers (1946-1964)
More informationDavid Gardner, BSc Pharm, MSc CH&E, PharmD Professor, Department of Psychiatry & College of Pharmacy
David Gardner, BSc Pharm, MSc CH&E, PharmD Professor, Department of Psychiatry & College of Pharmacy It s no dream. Sleep well without sleeping pills. Outline Baby boomers & beyond: medication use Deprescribing
More informationPresented by: Ontario s Geriatric Steering Committee
Polypharmacy: A Medication Management Opportunity Chris Fan-Lun, BScPhm, ACPR, CGP Clinical Practice Leader, Dept. of Pharmacy Services Mount Sinai Hospital, Sinai Health system Learning Objectives Provide
More informationObjective. A Multi Incident Analysis on Potentially Inappropriate Medication Use in Older Adults. Outline
A Multi Incident Analysis on Potentially Inappropriate Medication Use in Older Adults Kelly Ng BSc (Hons), PharmD Candidate Analyst, ISMP Canada 2015 Institute for Safe Medication Practices Canada. This
More informationFinding the sweet spot: Individualized targets for older adults with Type 2 DM
Finding the sweet spot: Individualized targets for older adults with Type 2 DM Samuel C. Durso, M.D., M.B.A. Mason F. Lord Professor of Medicine Director, Division of Geriatric Medicine and Gerontology
More informationScottish Medicines Consortium
Scottish Medicines Consortium ketoprofen/, 100mg/20mg; 200mg/20mg modified release capsules (Axorid ) No. (606/10) Meda Pharmaceuticals 05 February 2010 The Scottish Medicines Consortium (SMC) has completed
More informationDemystifying the Complex Patient
Demystifying the Complex Patient Jay Reaume, BSc, BScPhm, RPh, CDE Suzanne Singh, BScPhm, ACPR, PharmD, RPh May 30, 2015 Disclosures Jay Reaume No conflicts of interest to disclose Suzanne Singh No conflicts
More informationFall Prevention in Hospice (A pharmacologic and nonpharmacologic approach)
Fall Prevention in Hospice (A pharmacologic and nonpharmacologic approach) Chinenye Emereole, Pharm.D. Clinical Pharmacist Hospice Pharmacy Solutions Objectives Assess and identify hospice patients who
More informationKatee Kindler, PharmD, BCACP
Speaker Introduction Katee Kindler, PharmD, BCACP Current Practice: Clinical Pharmacy Specialist Ambulatory Care, St. Vincent Indianapolis Assistant Professor of Pharmacy Practice, Manchester University,
More informationDeprescribing Unnecessary Medications: A Four-Part Process
Deprescribing Unnecessary Medications: A Four-Part Process Scott Endsley, MD Fam Pract Manag. 2018;25(3):28-32. Abstract and Introduction Introduction www.medscape.com Ms. Horatio is a 76-year-old patient
More information2018 WPS MedicareRx Plan (PDP) Step Therapy
2018 WPS MedicareRx Plan (PDP) Step Therapy In some cases, the WPS MedicareRx Plan (PDP) requires you to first try certain drugs to treat your medical condition before we will cover another drug for that
More informationCOLCRYS-PST. Products Affected Step 1: Mitigare 0.6 mg capsule. Details. Step 2: Colcrys 0.6 mg tablet
COLCRYS-PST Mitigare 0.6 mg capsule Colcrys 0.6 mg tablet Criteria If the patient has tried one Step 1 product, authorization for a Step 2 product may be given. Exceptions can be made for a step 2 drug
More informationPolypharmacy and the Older Adult. Leslie Baker, PharmD, BCGP Umanga Sharma, MD
Polypharmacy and the Older Adult Leslie Baker, PharmD, BCGP Umanga Sharma, MD Objectives Identify what polypharmacy is Identify factors leading to polypharmacy Discuss consequences of polypharmacy Identify
More informationUse caution in the elderly: review of safe and effective medication use in older patients
Use caution in the elderly: review of safe and effective medication use in older patients John T. Holmes, PharmD, BCPS Assistant Professor of Family Medicine and Pharmacy Practice In support of improving
More informationOptimising Safe & Appropriate Medicines Use and Deprescribing. Katie Smith, Director, East Anglia Medicines Information Service February 2014
Optimising Safe & Appropriate Medicines Use and Deprescribing Katie Smith, Director, East Anglia Medicines Information Service February 2014 Background Objectives How & why the OSAMU document was developed
More informationLess is More: Introduction to Deprescribing
Less is More: Introduction to Deprescribing 7th Annual Pharmaceutical Care Conference Muscat, Oman Feb 23, 2017 Lindsay Yoo, BSc, BScPhm, RPh, CDE, CGP, PharmD Medication Safety Analyst, ISMP Canada About
More informationStrategies to Decrease Medication Errors in Elderly. Abeer Zeitoun, Pharm. D Certified in Medication Safety, MCPHS
Strategies to Decrease Medication Errors in Elderly Abeer Zeitoun, Pharm. D Certified in Medication Safety, MCPHS Road Map..Outline 1. Introduction A. Definitions B. Geriatrics: High risk population C.
More informationIF I M NOT TREATING WITH OPIOIDS, THEN WHAT AM I SUPPOSED TO USE?
NON-OPIOID TREATMENT OPTIONS FOR CHRONIC PAIN Alison Knutson, PharmD, BCACP Medication Management Pharmacist Park Nicollet Creekside Clinic Dr. Knutson indicated no potential conflict of interest to this
More informationDisclosure. The elderly at risk: reducing medications safely to meet life s changes. Relevant financial relationships.
The elderly at risk: reducing medications safely to meet life s changes Barbara Farrell BScPhm, PharmD, FCSHP European Society of Hospital Pharmacists Conference March 2017 Disclosure Relevant financial
More informationPolypharmacy: A Rational Evidence-informed Approach with a Touch of Common Sense
Polypharmacy: A Rational Evidence-informed Approach with a Touch of Common Sense KEEP CALM BECAUSE LESS IS MORE James McCormack B.Sc. (Pharm), Pharm.D. Professor Faculty of Pharmaceutical Sciences University
More informationCOMPOUNDING PHARMACY SOLUTIONS PRESCRIPTION COMPOUNDING FOR PAIN MANAGEMENT
JANUARY 2012 COMPOUNDING PHARMACY SOLUTIONS PRESCRIPTION COMPOUNDING WWW.CPSRXS. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: Osteoarthritis Pain
More informationSELECTED ABSTRACTS. Figure. Risk Stratification Matrix A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY
SELECTED ABSTRACTS A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY The authors of this article present a 4-quadrant matrix based on 2 key clinical parameters: risk for adverse gastrointestinal (GI)
More informationLONG -TERM USE OF PPIS: INDICATIONS, BENEFITS AND HARMS. Jihane Naous, M.D.
LONG -TERM USE OF PPIS: INDICATIONS, BENEFITS AND HARMS Jihane Naous, M.D. Objectives Identify the conditions supported by AGA/ACG guidelines necessitating long-term use of daily PPIs, Recognize which
More informationENSURING EXCELLENCE IN PRESCRIBING FOR OLDER ADULTS
ENSURING EXCELLENCE IN PRESCRIBING FOR OLDER ADULTS Philip J. Schneider, MS, FASHP The University of Arizona College of Pharmacy Learning Objectives: Describe the medication-use system and all interdependent
More informationPractical Guide to Safety of PPIs What to Tell Your Patient. Proton Pump Inhibitors
Practical Guide to Safety of PPIs What to Tell Your Patient Joel E Richter, MD, FACP, MACG Professor and Director Division of Digestive Diseases and Nutrition Joy Culverhouse Center for Esophageal Diseases
More informationRebecca Rottman-Sagebiel, Pharm.D., BCPS Sharon Jung Tschirhart, Pharm.D., BCPS Geriatric Clinical Pharmacy Specialists STVHCS, Audie L.
Rebecca Rottman-Sagebiel, Pharm.D., BCPS Sharon Jung Tschirhart, Pharm.D., BCPS Geriatric Clinical Pharmacy Specialists STVHCS, Audie L. Murphy Division Clinical Assistant Professors, University of Texas/UTHSCSA
More informationPharmaceutical Care for Geriatrics
Continuing Professional Pharmacy Development Program Pharmaceutical Care for Geriatrics Presented by: Alla El-Awaisi; MPharm, MRPharmS, MSc Event Organizer: Dr. Nadir Kheir; PhD Disclaimer: PRESENTING
More informationMeds and Falls: Keep in Step with your Meds
Meds and Falls: Keep in Step with your Meds Donna Bartlett PharmD, CGP, RPh Associate Professor-Pharmacy Practice MCPHS University Clinical Pharmacist-MCPHS University- Pharmacy Outreach Program donna.bartlett@mcphs.edu
More informationTransitions of Care & Medication Reconciliation Ashley King, PharmD, BCGP Clinical Pharmacist LECOM Health March 2018
Transitions of Care & Medication Reconciliation Ashley King, PharmD, BCGP Clinical Pharmacist LECOM Health March 2018 Objectives Identify when to complete medication reconciliation Understand the importance
More informationIf a bad thing is happening to a patient, a drug did it until proven otherwise
Dr Vicki s First Rule of Geriatrics Deprescribing in the Elderly Victoria Braund MD, FACP, CMD Director, Division of Geriatrics NorthShore University HealthSystem Medical Director, Brandel Health & Rehab
More informationSESSION 5 2:20 3:35 PM
SESSION 5 2:20 3:35 PM for the Primary Prevention of Cardiovascular Disease: A Personalized Approach SPEAKER Samia Mora MD, MHS Presenter Disclosure Information The following relationships exist related
More informationCOMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK
COMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK Robert L Alesiani, PharmD, CGP Chief Pharmacotherapy Officer CareKinesis, Inc. (a Tabula Rasa Healthcare Company) 2 3 4 5 Pharmacogenomics
More informationCOLCRYS-PST. Products Affected Step 1: Mitigare 0.6 mg capsule. Details. Step 2: Colcrys 0.6 mg tablet
COLCRYS-PST Mitigare 0.6 mg capsule Colcrys 0.6 mg tablet Criteria If the patient has tried one Step 1 product, authorization for a Step 2 product may be given. Exceptions can be made for a step 2 drug
More informationCommon Antidepressant Medications for Adults
(and Citalopram (Celexa) Escitalopram (Lexapro) Fluoxetine (Prozac) Fluoxetine Weekly (Prozac Weekly) 20 in AM w/ food (10 mg in elderly or those w/ panic disorder) 20 40 40 (If age >60yo, max 20) 10 10
More informationThe Flozins Quest for Clarity?
The Flozins Quest for Clarity? Choosing Wisely with Academic Detailing 2018 ARE THEY THE REAL DEAL Disclosure statements The Academic Detailing Service is operated by Dalhousie Continuing Professional
More informationOBJECTIVES. Key issues in geriatric pharmacology. Effects of age on pharmacokinetics and pharmacodynamics
PHARMACOTHERAPY 1 OBJECTIVES 2 Know and understand: Key issues in geriatric pharmacology Effects of age on pharmacokinetics and pharmacodynamics Risk factors for adverse drug events for older patients
More informationDementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist
Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution
More informationManagement of high risk MMT patients. Meldon Kahan MD Methadone Prescribers Conference Toronto, Nov 15, 2013
Management of high risk MMT patients Meldon Kahan MD Methadone Prescribers Conference Toronto, Nov 15, 2013 CFPC CoI Templates: Slide 1 Faculty Disclosure Faculty: Meldon Kahan Relationships with commercial
More informationManaging Pain in the Elderly
Managing Pain in the Elderly MILES BELGRADE, MD COMPREHENSIVE PAIN CENTER MINNEAPOLIS VA The Pain Deck is Stacked Against the Elderly Osteoporosis Fractures 1 Zoster & PHN Trigeminal Neuralgia Verne 81-year-old
More informationIbuprofen. Ibuprofen and Paracetamol: prescribing overview. Ibuprofen indications CYCLO-OXYGENASE (COX I) CYCLO-OXEGENASE (COX II) INFLAMMATORY PAIN
Ibuprofen Ibuprofen and Paracetamol: prescribing overview Sarah Holloway Macmillan CNS in palliative care NSAID Non-selective COX inhibitor Oral bioavailability: 90% Onset of action: 20-30 mins (can take
More informationMaximizing Medication Safety UNIVERSITY OF HAWAII AUGUST 31, 2016
Maximizing Medication Safety UNIVERSITY OF HAWAII AUGUST 31, 2016 Adverse Drug Events (ADE s) RISK FACTORS FOR Adverse Drug Events (ADEs) 6 or more concurrent chronic conditions 12 or more doses of drugs/day
More informationdisease or in clients who consume alcohol on a regular basis. bilirubin
NON-OPIOID Acetaminophen(Tylenol) Therapeutic class: Analgesic, antipyretic Aspirin (ASA, Acetylsalicylic Acid) Analgesic, NSAID, antipyretic Non-Opioid Analgesics COMMON USES WHAT I NEED TO KNOW AS A
More informationFamily Medicine Pharmacotherapy Update: What s here and what s coming. Sarah Amering, PharmD, BCACP 4 March 2018
Family Medicine Pharmacotherapy Update: What s here and what s coming Sarah Amering, PharmD, BCACP 4 March 2018 Objectives Provide a brief overview of primary care related new drug approvals in 2017 and
More informationPharmacology in the Elderly
Pharmacology in the Elderly James Hardy Geriatrician, Royal North Shore Hospital A recent consultation Aspirin Clopidogrel Warfarin Coloxyl with senna Clearlax Methotrexate Paracetamol Pantoprazole Cholecalciferol
More informationALZHEIMER'S DRUGS. Details. Step 2: Exelon Patch 13.3 mg/24 hour transdermal Exelon Patch 4.6 mg/24 hr transdermal
ALZHEIMER'S DRUGS Products Affected Step 1: donepezil 10 mg disintegrating tablet donepezil 10 mg tablet donepezil 23 mg tablet donepezil 5 mg disintegrating tablet donepezil 5 mg tablet galantamine 12
More informationNSAIDs Overview. Souraya Domiati, Pharm D, MS
NSAIDs Overview Souraya Domiati, Pharm D, MS Case A 32 years old shows up into your pharmacy asking for an NSAID for his ankle pain He smokes1 pack/day His BP is 125/75mmHg His BMI is 35kg/m2 His is on
More informationHA CONVENTION Effectiveness of Pharmacist-led Frail Elderly Medication Service in Acute Geriatric Ward
Effectiveness of Pharmacist-led Frail Elderly Medication Service in Acute Geriatric Ward HA CONVENTION 2017 Candis Chang Pharmacist Department of Pharmacy Ruttonjee and Tang Shiu Kin Hospitals Background
More informationPain Management in a Geriatric Population. Alan Obringer RPh, CPh, CGP Executive Director Senior Care Pharmacy of Florida
Pain Management in a Geriatric Population Alan Obringer RPh, CPh, CGP Executive Director Senior Care Pharmacy of Florida Objectives Review definitions and types of pain Discuss purpose and value of pain
More informationCHAPTER 2. GERIATRICS, SELF-ASSESSMENT QUESTIONS
CHAPTER 2. GERIATRICS, SELF-ASSESSMENT QUESTIONS 1. The following is an accurate description of the aging population: A. The number of older adults will reach 17 million in 2030 B. The ratio of women to
More informationAppropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist
Appropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist Disclosures I have no actual or potential conflicts of interest to report in relation to this
More informationLearning Objectives 2/4/2016. Patrick Leung, Pharm.D., BCPS, PhC. Patrick Leung, Pharm.D., BCPS, PhC Davena Norris, Pharm.D., BCPS, PhC 2/20/2016
Patrick Leung, Pharm.D., BCPS, PhC Davena Norris, Pharm.D., BCPS, PhC 2/20/2016 Learning Objectives Identify age-related pharmacokinetic and pharmacodynamic changes in older adults. Utilization the START/STOPP
More informationJennifer Loh, MD, FACE Chief of Endocrinology KP Hawaii AAMD of Medical Education, KP Hawaii
Individualized Diabetes Treatment for the Elderly Jennifer Loh, MD, FACE Chief of Endocrinology KP Hawaii AAMD of Medical Education, KP Hawaii Extremely Relevant Baby Boomers are aging! ¼ of people age
More information1/16/2018. Disclosure Information. Objectives. Geriatric Scalpel: Improving Lives of Older Adults Through Rational Deprescribing
Geriatric Scalpel: Improving Lives of Older Adults Through Rational Deprescribing Abhilash K. Desai, MD Geriatric Psychiatrist Idaho Memory & Aging Center, PLLC Adjunct Associate Professor Saint Louis
More informationTreatment of Neuropathic Pain: What Does the Evidence Say? or Just the Facts Ma am
Treatment of Neuropathic Pain: What Does the Evidence Say? or Just the Facts Ma am Tim R Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy Cleveland Clinic Akron General Center for Family
More informationNEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES
NEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES GENERAL PRINCIPLES Neuropathic pain may be relieved in the majority of patients by multimodal management A careful history and examination are essential.
More informationClinical and Contextual Evidence Reviews
Clinical and Contextual Evidence Reviews Roger Chou, MD Professor of Medicine Oregon Health & Science University Director, Pacific Northwest Evidence-based Practice Center Purpose Summarize methods for
More informationHealth Economics 101: PPI prescriptions in the Emergency Room
: PPI prescriptions in the Emergency Room Canadian Optimal Medication Prescribing & Utilization Service (COMPUS) Presented by: Chris Cameron October 26, 2007 What is Health Economics? Health economics
More informationTERICOX. Composition Each film-coated tablet contains 60, 90, or 120 mg of Etoricoxib.
TERICOX Composition Each film-coated tablet contains 60, 90, or 120 mg of Etoricoxib. Tablets Action Tericox is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic,
More informationPrescribing in the Elderly. Dr Alison Macrae and Dr Debbie Vest GPST2 Drs in Psychiatry
Prescribing in the Elderly Dr Alison Macrae and Dr Debbie Vest GPST2 Drs in Psychiatry 24 th September 2014 Objectives Understand the significance of polypharmacy in the elderly Become familiar with the
More informationOverview of Essentials of Pain Management. Updated 11/2016
0 Overview of Essentials of Pain Management Updated 11/2016 1 Overview of Essentials of Pain Management 1. Assess pain intensity on a 0 10 scale in which 0 = no pain at all and 10 = the worst pain imaginable.
More informationA Call to Action: Addressing Diabetes Medication Safety
A Call to Action: Addressing Diabetes Medication Safety Evan M. Klass, M.D., F.A.C.P. Senior Associate Dean, Statewide Initiatives Reducing ED visits for insulin induced hypoglycemia is a Healthy People
More informationMANAGEMENT OF DIABETIC NEUROPATHY. Chungnam University Hospital Soo-Kyung, Bok, M.D., Ph.D.
MANAGEMENT OF DIABETIC NEUROPATHY Chungnam University Hospital Soo-Kyung, Bok, M.D., Ph.D. The Diabetic neuropathy cannot be reversed Not to restore function to damaged nerve Slowly progress no initial
More informationHigh-Decile Prescribers: All Gain, No Pain?
High-Decile Prescribers: All Gain, No Pain? Len Paulozzi, MD, MPH National Center for Injury Prevention and Control Centers for Disease Control and Prevention National Center for Injury Prevention and
More informationChitra Fernando, MD March 18, 2008
Chitra Fernando, MD March 18, 2008 Definition Statistics Risk factors Why older adults are more prone to ADE Manifestations Inappropriate medications for older adults What can be done to minimize adverse
More informationTaking the harm out of Polypharmacy Step by step. Karen Reid and Claire Stein Lead Integrated Care Pharmacist NHS Lothian
Taking the harm out of Polypharmacy Step by step Karen Reid and Claire Stein Lead Integrated Care Pharmacist NHS Lothian Presentation: Polypharmacy Overview of the 2015 guidelines The Seven Steps Application
More informationAlgorithm for Use of Non-steroidal Anti-inflammatories (NSAIDs)
Algorithm for Use of Non-steroidal Anti-inflammatories (NSAIDs) Page 3 Publisher Conseil du médicament www.cdm.gouv.qc.ca Coordination Anne Fortin, Pharmacist Development Conseil du médicament Fédération
More informationNOTOPAIN CAPLETS. Diclofenac Sodium + Paracetamol. Composition. Each tablet contains: Diclofenac Sodium BP 50mg Paracetamol BP 500mg.
NOTOPAIN CAPLETS Diclofenac Sodium + Paracetamol Composition Each tablet contains: Diclofenac Sodium BP 50mg Paracetamol BP 500mg Pharmacology Phamacodynamics Diclofenac relieves pain and inflammation
More informationPain Management Management in Hepatic Hepatic and and Renal Dysfunction
Pain Management in Hepatic and Renal Dysfunction Review the pharmacologic basis for medications used in pain management Identify pain medications which hshould ldbe avoided in patients with hepatic dysfunction
More informationSTOPP and START criteria October 2011
# START and STOPP are newer criteria to identify potentially inappropriate medications in elderly, including drug drug and drug disease interactions, drugs which increase risk of falls and drugs which
More informationMichelle Greiver Simone Dahrouge Patricia O Brien Donna Manca Marie-Thérèse Lussier
Michelle Greiver Simone Dahrouge Patricia O Brien Donna Manca Marie-Thérèse Lussier University of Toronto Practice Based Research Network Ottawa Practice Enhancement Network Quality & Innovation Program,
More informationThe epidemiology of polypharmacy
The epidemiology of polypharmacy Dr Rupert Payne University of Cambridge The ageing population ONS, 2010 The burden of multimorbidity Barnett K, Lancet 2012 The burden of multimorbidity Barnett K, Lancet
More informationAdjusting and Withdrawing Medications in the Elderly
Adjusting and Withdrawing Medications in the Elderly Louise Mallet, B.Sc.Pharm., Pharm.D., CGP Professor in Clinical Pharmacy, Faculty of Pharmacy, University of Montreal Clinical Pharmacist in Geriatrics,
More informationPOLYPHARMACY IN OLDER ADULTS AND BEERS CRITERIA UPDATE
POLYPHARMACY IN OLDER ADULTS AND BEERS CRITERIA UPDATE Jeannie Kim Lee, PharmD, BCPS, CGP Clinical Pharmacy Director College of Pharmacy The University of Arizona Learning Objectives: State the risks of
More informationOptimizing Non-Opioid Therapy for Chronic Pain
Optimizing Non-Opioid Therapy for Chronic Pain Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means
More informationBEERs For the Elderly
BEERs For the Elderly February 2008 Presented by:carla Ambrosini Seniors First Clinic Pharmacist 12/05/2008 1 Objectives To highlight the overall health care impact of drug related adverse reactions and
More information2018 STEP THERAPY CRITERIA UCare Connect + Medicare (SNBC) (HMO SNP) UCare s Minnesota Senior Health Options (MSHO) (HMO SNP)
2018 STEP THERAPY CRITERIA UCare Connect + Medicare (SNBC) (HMO SNP) UCare s Minnesota Senior Health Options (MSHO) (HMO SNP) In some cases, UCare s MSHO and UCare Connect + Medicare require you to first
More information